Brilacidin, A Candidate Drug For The Treatment of COVID-19 Huateng

1. Huateng Pharma https://en.huatengsci.com Brilacidin, A Candidate Drug For The Treatment of COVID-19 Brilacidin, an investigational new drug, is a polymer-based antibiotic. It represents a new class of antibiotics called host defense protein mimetics, or HDP-mimetics, which are non-peptide synthetic small molecules that mimic host defense peptides (HDPs). HDPs ( also called antimicrobial peptides) is part of the innate immune response. On Jan 14, 2021, Brilacidin has been granted Fast Track designation by the FDA for the treatment of COVID-19. Brilacidin is a first-in-class host defense protein mimetic with antiviral, anti-inflammatory and antibacterial properties. Early data has shown that this drug exerts potent in vitro antiviral activity against SARS-CoV-2. For more information, click here to read the paper titled: Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2. Click here to read a peer-reviewed article titled: Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture in the journal Viruses that supports Brilacidin's potential as a COVID-19 treatment. The Brilacidin trial for the treatment of COVID-19 infection has started in February

2. Huateng Pharma 2021 and is expected to be completed in July 2021. The study is a randomized, blinded, placebo-controlled, parallel group design and will accept 120 patients. At present, Brilacidin is being evaluated in a Phase 2 clinical trial in hospitalized COVID-19 patients. https://en.huatengsci.com Huateng Pharma, a leading company focusing on R&D and production of pharmaceutical intermediates for customers all over the world. We have our own industry park and our capabilities include rapid initial scale-up and custom synthesis with the capacity to produce up to tons. We supply 4,6-Pyrimidine dicarboxylic acid (CAS NO. 16490-02-1) with high quality which is an intermediate for Brilacidin. References: [1] FDA Fast Tracks Brilacidin for COVID-19 Treatment [2] Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2 [3] Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture